{"entity":{"id":"nct07019675","kind":"trial","name":"A Study of SKB518 in Patients With Lung Cancer","aka":[],"tldr":"A phase 2 trial of Tislelizumab and Carboplatin in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","summary":"A Study of SKB518 in Patients With Lung Cancer is a phase 2 interventional study registered as NCT07019675 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 192 participants planned, started 2025-08-29 and due to reach its primary completion in 2027-02-20. Interventions recorded: SKB518, Tislelizumab and Carboplatin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07019675","url":"https://clinicaltrials.gov/study/NCT07019675"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tislelizumab","carboplatin"],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07019675","phase":"2","setting":"A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of SKB518 in Patients With Lung Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","enrolled":192,"outcomes":[]},"route":"/trials/nct07019675/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}